Case Report

Varying Presentations of Multisystem Inflammatory Syndrome Temporarily Associated with COVID-19

Jasmina Krikilion, Lisa Nuyttens, Siel Daelemans, Karlien François, Reiner Mauel, Daniel De Wolf, and Gerlant van Berlaer

1Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Department of Paediatrics, Brussel, Belgium
2Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Division of Nephrology and Hypertension, Brussel, Belgium
3Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Paediatric Emergency and Intensive Care Unit, Brussel, Belgium

Correspondence should be addressed to Gerlant van Berlaer; gerlant.vanberlaer@uzbrussel.be

Received 6 July 2020; Revised 5 November 2020; Accepted 7 November 2020; Published 24 November 2020

Academic Editor: Marie Louise von Linstow

Copyright © 2020 Jasmina Krikilion et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. A novel coronavirus identified in 2019 leads to a pandemic of severe acute respiratory distress syndrome with important morbidity and mortality. Initially, children seemed minimally affected, but there were reports of cases similar to (atypical) Kawasaki disease or toxic shock syndrome, and evidence emerges about a complication named paediatric inflammatory multisystem syndrome temporarily associated with SARS-CoV-2 (PIMS-TS) or multisystem inflammatory syndrome in children (MIS-C). Case Presentations. Two cases were compared and discussed demonstrating varying presentations, management, and evolution of MIS-C. These cases are presented to increase awareness and familiarity among paediatricians and emergency physicians with the different clinical manifestations of this syndrome. Discussion. MIS-C may occur with possible diverse clinical presentations. Early recognition and treatment are paramount for a beneficial outcome.

1. Introduction

In December 2019, a novel coronavirus was identified in Wuhan (China) as the cause of an atypical pneumonia which may cause severe acute respiratory distress syndrome. The virus rapidly spread around the world and became a global pandemic. The virus was named “severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)” by the World Health Organization. The disease has been termed “COVID-19” [1].

In Belgium, the first case was diagnosed in February 2020. During the following months, more information became available about the course of the disease. In children, a SARS-CoV-2 infection is usually asymptomatic or mild [2]. However, more reports emerged of a presentation in children similar to Kawasaki disease or toxic shock syndrome [3, 4]. The syndrome has been named multisystem inflammatory syndrome in children (MIS-C), paediatric multisystem inflammatory syndrome, paediatric inflammatory multisystem syndrome temporarily associated with SARS-CoV-2 (PIMS-TS), or paediatric hyperinflammatory syndrome [5] and has been defined by the CDC (see Table 1) and the WHO (see Table 2) [6, 7].

In our tertiary teaching hospital, we detected two cases of MIS-C that are worthwhile comparing, discussing, and sharing with the wider paediatric community, in order to optimize early recognition and management of MIS-C.

Both patients provided informed consent, and approval of the Ethical Committee was granted.

2. Case Presentation 1

The first case concerns a 15-year-old boy, known with idiopathic end-stage kidney disease (ESKD) treated with
peritoneal dialysis. He had no history of cardiac dysfunction. He was admitted on March 6th, 2020, for a deceased-donor kidney transplantation which was postponed because of fever for 3 days. He complained of fatigue, headaches, and loss of appetite. Characteristics and laboratory findings at admission and imaging results are noted in Table 3. A positive PCR for SARS-CoV-2 confirmed COVID-19 the day of admission. He was hospitalized for 10 days because isolation measures were not possible at home. He stayed paucisymptomatic and received supportive care with antipyretics besides his usual treatments for kidney failure. After 10 days, he was discharged home.

Twenty-three days after discharge, he was readmitted because of dyspnea (NYHA grade III), orthopnea, and hemoptysis. Laboratory findings and imaging results are shown in Table 3. Because of suspected alveolar hemorrhage, bronchoscopy was performed the day after admission. Repeated bronchoalveolar lavage ruled out alveolar bleeding. SARS-CoV-2 PCR on lower respiratory samples was negative. Because of progressive oxygen requirements after bronchoscopy and severe myocardial dysfunction on echocardiography, the patient was transferred to the intensive care unit for monitoring, inodilator therapy, and noninvasive ventilation (NIV) with rapid clinical recovery. NIV could be stopped, and supplemental oxygen was given by high-flow nasal cannula until day 4 of hospitalization. Endomyocardial biopsy was performed, but neither endomyocardial PCR nor histopathological analysis was suggestive for SARS-CoV-2 myocarditis. Cardiac MRI on day 8 revealed a dilated left ventricle with reduced ejection fraction of 30–35%. Coronarography revealed normal coronary anatomy.

While titrating heart failure therapy, he needed readmission in the medium care unit from day 9 to 12 because of an episode of relapse cardiac decompensation that needed to be managed by increasing ultrafiltration through peritoneal dialysis.

Between day 18 and 20, he developed a low-degree fever (maximum body temperature of 38.7°C axillary). C-reactive protein was low, and lymphocytosis was absent. Because of the suspicion of pneumonia, co-amoxiclav was empirically started. All cultures (blood, sputum, peritoneal fluid, and urine) yielded negative. Because of nocturnal hypoxemia, a polysomnography was performed revealing Cheyne–Stokes apneas secondary to heart failure. After 28 days, he was ready for a new discharge home. He is still under medical follow-up for his end-stage kidney disease and slowly recovering heart failure.

This patient was one of the first cases of pediatric SARS-CoV-2 infection in Belgium. In retrospect, we think he was one of the first cases of a MIS-C associated with a SARS-CoV-2 infection in Europe, with signs of viral or inflammatory myocarditis. At that time, little was known about the treatment of a MIS-C associated with COVID-19 infection, so no immunoglobulins or corticoids were administered during his stay.

### 3. Case Presentation 2

The second case, a girl of 14 years old, known with Lennox–Gastaut syndrome, was admitted on April 28th, 2020, in our hospital for neurological observation after a severe concussion. The second day of admission, she developed high fever initially not responding to antipyretics, and she became generally unwell with a dry cough. The patient and her mother had COVID-19-like symptoms approximately a month prior to admission; unfortunately, no confirmation with PCR-testing for SARS-CoV-2 was obtained at that time. Additional characteristics, laboratory findings, and chest X-ray results are shown in Table 3.

Epileptic activity increased, and she needed seizure medication. Because of seizures and the risk of aspiration pneumonia, intravenous co-amoxiclav was empirically initiated. She gradually deteriorated needing oxygen therapy. Because fever persisted and inflammation parameters were rising, intravenous antibiotic therapy was switched to third generation cephalosporins. Cardiac ultrasound, ECG, and
Table 3: Comparing clinical signs and symptoms, lab and imaging, and treatment and outcome for two cases of MIS-C.

| Characteristics     | Case 1       | Case 2       |
|---------------------|--------------|--------------|
| Gender              | Male         | Female       |
| Age (years)         | 15           | 14           |
| Weight (kg)         | 60           | 67           |
| BMI (kg/m²)         | 19.59        | 21.88        |
| Signs and symptoms  |              |              |
| Fever               | Yes          | No           |
| Cough, dyspnea      | Yes          | Yes          |
| Sore throat         | No           | Yes          |
| Decreased appetite  | No           | Yes          |
| Nausea, vomiting    | No           | No           |
| Diarrhoea           | No           | No           |
| Fatigue             | Yes          | Yes          |
| Headache            | Yes          | No           |
| Rash                | Yes          | No           |
| Desaturation <92%   | No           | Yes          |
| Edema               | No           | Yes          |
| PICU referral        |              |              |
| Reason of referral  | No PICU referral | Respiratory deterioration with early signs of shock |
| Organ support       | None         | NIV          |
| Pharmacological     | None         | Vasopressins, antibiotics, diuretics, morphin |
| treatment           |              |              |
| LOS in hospital     | 10           | 28           |
| LOS in PICU         | 0            | 7            |
| Imaging result      |              |              |
| Chest X-ray         | Normal       | Bilateral consolidations |
| Chest CT            | No           | Bilateral consolidations |
| Heart ultrasound    | No           | (i) Dilated left ventricle, ejection fraction 30–35%.
|                     |              | (ii) Diastolic dysfunction grade 1 |
|                     |              | (iii) Normal right ventricle |
|                     |              | (iv) Dilated left atrium |
|                     |              | (v) MI 2/4, TI 1/4, dilated truncus pulmonalis |
|                     |              | (vi) Pericardial effusion (5 mm), no hemodynamical consequences |
| ECG                 | Normal       | Negative T-waves in the anterior wall with prolonged QT-segment (534 ms) |
|                     |              | Peripheral low voltages with flattened T-waves in left precordials |
| Lab results         |              |              |
|                     | (i) Lymphopenia (929/mm³) | (i) Lymphopenia (267/mm³) |
|                     | (ii) No thrombocytopenia or thrombocytosis | (ii) Thrombocytosis (808,000/mm³) |
|                     | (iii) Anemia: hemoglobin 7.3 g/dL | (iii) Hemoglobin 7.6 g/dL |
|                     | (iv) CRP 56.6 mg/L | (iv) CRP 304.3 mg/L (maximum) |
|                     | (v) Albumin 26 g/L | (v) Albumin 24 g/L |
|                     | (vi) Normal hepatic enzymes | (vi) Cardiac enzymes: |
| Microbiology results| (vii) Cardiac enzymes: | (a) NT-proBNP 155919.0 ng/L |
|                     | (a) NT-proBNP 155919.0 ng/L | (b) Cardiac troponin T 0.314 µg/L |
|                     | (b) Cardiac troponin T 0.314 µg/L | (vii) D-dimer 3584 ng/ml |
|                     | (viii) D-dimer 6943 ng/ml | (viii) Fibrinogen 322 mg/dL |
|                     | (ix) Fibrinogen 482 mg/dL | |
|                     | (x) Fibrinogen 482 mg/dL | |

Notes:
- Crude values are reported for continuous variables.
- Laboratory results are reported with reference ranges.
- Microbiological results include specific tests for SARS-CoV-2 and other relevant pathogens.
- Treatment and outcomes are based on clinical management strategies and outcomes reported in the provided cases.

Case Reports in Pediatrics
Echocardiography were planned, as well as a chest CT which all showed signs of pericarditis (see Table 3).

Our patient did not meet the criteria for Kawasaki disease but appeared to be an atypical Kawasaki-like shock syndrome. A trial of intravenous immunoglobulins (IVIGs) was administered. Although none of the cultures (blood, cerebrospinal fluid, urine, stool, and bronchial aspirates) yielded positive, antibiotics were continued for 10 days. Shortly after IVIG treatment, the patient clinically improved significantly although moderate fever persisted and inflammatory parameters dropped swiftly (as visualized in Figure 1). Oxygen therapy was interrupted, and all edema disappeared. In the light of clinical and laboratory improvement to normalization, there seemed no need for additional corticotherapy.

After hospital discharge, SARS-CoV-2 serology returned positive and diagnosis of MIS-C associated with COVID-19 was confirmed. She remains under medical follow-up for her epilepsy but recovered completely from PIMS-TS.

4. Discussion

Multisystem inflammatory syndrome in children (MIS-C) is an uncommon entity. During this global pandemic with SARS-CoV-2, some paediatric cases emerged demonstrating a formerly unknown complication of COVID-19, meeting criteria of typical or atypical Kawasaki disease, toxic shock syndrome, and macrophage activation syndrome [3, 8, 9]. Our cases fulfilled the definition of MIS-C, as described by the Centre for Disease Control (CDC) in the USA [6] or by the World Health Organization (WHO) [7].

It is noteworthy that these new developing cases are generally older (teenagers) than the typical Kawasaki patient, who is generally younger than six years old.

Comparing the two cases in this study with other cases described in the literature, we note that MIS-C is mostly described in patients with following characteristics: young adolescents, African origin, and BMI >25 kg/m² [3, 8, 10]. Our cases absolutely match those characteristics. Both cases were young teens of African origin; patient 1 had a normal BMI, whereas patient 2 had a BMI above 95th percentile. Although the basic features are similar in our two patients, there is a variation in clinical presentation: Case 1 presented with respiratory distress and heart failure, whereas patient 2 presented with symptoms similar to toxic shock syndrome. In the literature, a wide variety of clinical presentations is described although they have the same underlying entity [3, 8]. Pathogenesis is not yet fully understood.

Early recognition of MIS-C is paramount for a beneficial outcome, but recognition is complicated by the wide variety in initial clinical presentation and difficulties in interpretation of additional investigations. During the COVID-19 pandemic, high suspicion should be raised in every child presenting with signs of sepsis or vasculitis. In those children, additional investigations to confirm infection with SARS-CoV-2 are indicated; however, they are not always sensitive: with a sensitivity of only 71–98%, a negative PCR for SARS-CoV-2 does not rule out a SARS-CoV-2 infection [3, 9, 11]. Patient 2 had a negative PCR twice, but serology confirmed diagnosis. This patient did have a possible COVID-19 exposure a few weeks prior to admission. As described in the literature, MIS-C can occur in the acute phase of COVID-19 but also as a post-inflammatory syndrome [12]. Although chest CT in acute COVID-19 in adults is very sensitive [13], imaging of the chest in children with MIS-C can be normal [8, 10]. Close cardiac monitoring is warranted although cardiac ultrasound does not always reveal abnormalities [8, 10].
sampling of cardiac enzymes should be done in every child with suspicion of MIS-C [4]. This often shows elevation of D-dimers, NT-proBNP, troponins, and fibrinogen, as seen in our first case (fibrinogen in the second case was not tested in the acute phase of disease) [14]. These laboratory results are not often seen in typical Kawasaki which can help guide diagnosis.

In treating MIS-C, a multidisciplinary approach is desirable as all organ systems can be involved and associated morbidity and mortality is described in the literature [3, 8].

Antibiotic therapy is often initiated because of the clinical resemblance to toxic shock syndrome and sepsis and the high inflammatory parameters. Both patients in this study were empirically started on antibiotics as per sepsis protocol, but in both cases all cultures yielded negative. Thus, in suspicion of MIS-C, antibiotics can be stopped early if cultures stay negative after 48 hours.

In MIS-C, imminent treatment with intravenous immunoglobulins is associated with a beneficial outcome. In our cases, patient 2 showed swift improvement with IVIG alone. Case 1 did not receive any treatment other than supportive treatment. We can only speculate that additional treatment might have improved his course of disease and length of hospital stay. Suggested management in other case reports includes intravenous immunoglobulins or corticoids [3, 12]. In one case report, the patient was treated with tocilizumab, an IL-6 receptor antagonist [10]. A study published in April 2020 showed significant clinical improvement after administration of tocilizumab to patients with COVID-19 pneumonia associated with acute respiratory distress syndrome [9].

We are convinced that sharing the features in this subset of children will enhance the awareness for MIS-C in the wider paediatric community and may help to optimize early recognition and management of this novel syndrome.

Abbreviations

BMI: Body mass index
CDC: Centre for Disease Control (USA)
COVID-19: Coronavirus disease-19
CRP: C-reactive protein
CT: Computer tomography
ECG: Electrocardiogram
ESKD: End-stage kidney disease
IVIG: Intravenous immunoglobulins
MIS-C: Multisystem inflammatory syndrome in children
MRI: Magnetic resonance imaging
NIV: Noninvasive ventilation
NT-proBNP: N-terminal pro-brain natriuretic peptide
PCR: Polymerase chain reaction
PIMS-TS: Paediatric inflammatory multisystem syndrome temporarily associated with SARS-CoV-2
SARS-CoV-2: Severe acute respiratory syndrome coronavirus type 2.

Data Availability

All data generated or analyzed during this study are included in this published article. Additional data are available upon simple request to the corresponding author. All authors confirm that they had full access to all of the data in the study and they can take responsibility for the integrity of the data and the accuracy of the data analysis.

Ethical Approval

The study obtained ethics approval from the Ethical Committee of the Universitair Ziekenhuis Brussel (O.G. 016) (reference number B14320320000140).

Consent

All participants’ legal guardians provided written informed consent for the collection of data and publication.

Disclosure

Gerlant van Berlaer, the manuscript’s guarantor, affirms that the manuscript is an honest, accurate, and transparent account of the study being reported and that no important aspects of the study have been omitted. The authors performed this research as part of their employment at Universitair Ziekenhuis Brussel, Brussels, Belgium.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Drs. Krikilion J. and Nuyttens L. contributed equally to this work. GvB, JK, and LN conceived and designed the study. GvB, JK, LN, KF, SD, RM, and DDW are the main investigators. GvB, JK, LN, KF, SD, RM, and DDW analyzed the data. JK, LN, and GvB wrote the paper. GvB, JK, LN, KF, SD, RM, and DDW corrected the final text. All authors read and approved the final manuscript.

References

[1] World Health Organization, Coronavirus, World Health Organization, 2020, https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
[2] N. Parri, M. Lenge, and D. Buonsenso, “Children with COVID-19 in pediatric emergency departments in Italy,” New England Journal of Medicine, vol. 383, no. 2, p. 187, Article ID NEJMc2007617, 2020.
[3] S. Riphagen, X. Gomez, C. Gonzalez-Martinez, N. Wilkinson, and P. Theodoris, “Hyperinflammatory shock in children during COVID-19 pandemic,” The Lancet, vol. 395, no. 10237, pp. 1607-1608, 2020.
[4] Royal College of Paediatrics and Child Health, Guidance: Paediatric Multisystem Inflammatory Syndrome Temporarily Associated with COVID-19, Royal College of Paediatrics and Child Health, London, UK, 2020, https://www.rcpch.ac.uk/sites/default/files/2020-05/COVID-19-Paediatric-multisystem-inflammatory Syndrome-20200501.pdf.
[5] World Health Organization, *Multisystem Inflammatory Syndrome in Children and Adolescents Temporally Related to COVID-19 [Scientific Brief]*, World Health Organization, Geneva, Switzerland, 2020, https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19.

[6] Center for Disease Control and Prevention (CDC), *Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Children (MIS-C)*, Center for Disease Control and Prevention (CDC), Atlanta, GA, USA, 2020, https://www.cdc.gov/mis-c/hcp/.

[7] World Health Organization (WHO), *Multisystem Inflammatory Syndrome in Children and Adolescents with COVID-19*, World Health Organization, Geneva, Switzerland, 2020, https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19.

[8] F. Licciardi, G. Pruccoli, M. Denina et al., “SARS-CoV-2-induced Kawasaki-like hyperinflammatory syndrome: a novel COVID phenotype in children,” *Pediatrics*, vol. 146, no. 2, Article ID e20201711, 2020.

[9] P. Toniati, S. Piva, M. Cattalini et al., “Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in brescia, Italy,” *Autoimmunity Reviews*, vol. 19, no. 7, Article ID 102568, 2020.

[10] S. Balasubramanian, T. M. Nagendran, B. Ramachandran, and A. V. Ramanan, “Hyper-inflammatory syndrome in a child with COVID-19 treated successfully with intravenous immunoglobulin and tocilizumab,” *Indian Pediatrics*, vol. 57, no. 7, pp. 681–683, 2020.

[11] J. Watson, P. F Whiting, and J. E Brush, “Interpreting a COVID-19 test result,” *BMJ (Clinical Research ed.)*, vol. 369, p. m1808, 2020.

[12] T. R. Hennon, M. D. Penque, R. Abdul-Aziz et al., “COVID-19 associated multisystem inflammatory syndrome in children (MIS-C) guidelines; a Western New York approach,” *Progress in Pediatric Cardiology*, vol. 57, Article ID 101232, 2020.

[13] A. Bernheim, X. Mei, M. Huang et al., “Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection,” *Radiology*, vol. 295, no. 3, pp. 200463–200691, 2020.

[14] B. M. Henry, S. W. Benoit, M. H. S. de Oliveira et al., “Laboratory abnormalities in children with mild and severe coronavirus disease 2019 (COVID-19): a pooled analysis and review,” *Clinical Biochemistry*, vol. 81, p. 1, 2020.